Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29969139 | 0.97 | CA1 (0.50) | CA1CA2POLBL3MBTL1MEN1 | |
| SCHEMBL4141702 | 0.84 | — | — | |
| SCHEMBL11688163 | 0.84 | CA1 (0.69) | CA1CA2POLBL3MBTL1KMT2A | |
| SCHEMBL48487 | 0.77 | POLB (0.45) | POLBL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL1606347 | 0.77 | L3MBTL1 (0.47) | POLBL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL2969669 | 0.74 | POLB (0.43) | POLBL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL1487100 | 0.74 | CA1 (0.50) | CA1CA2POLBL3MBTL1NPSR1 | |
| SCHEMBL8268468 | 0.74 | POLB (0.43) | POLBL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL9663002 | 0.74 | POLB (0.43) | POLBL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL2778744 | 0.74 | POLB (0.43) | POLBL3MBTL1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116754695-B | Derivatization detection method for chlorosulfonyl isocyanate | 长沙晨辰医药科技有限公司 | 2023-11-03 | — | — | CN | claimed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | disclosed |
| CN-115322176-B | 2, 3-dihydrobenzofuranyl substituted 1H-indazole compound and preparation and application thereof | 温州医科大学 | 2024-04-16 | — | — | CN | disclosed |
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-02 | — | — | US | disclosed |
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-02 | — | — | US | disclosed |
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-02 | — | — | US | disclosed |
| CN-116754695-B | Derivatization detection method for chlorosulfonyl isocyanate | 长沙晨辰医药科技有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-0873123-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997017070-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-05-15 | — | — | WO | disclosed |
| US-5373000-A | Antibacterial agent against both grampositive and gramnegative bacterias | EISAI CO., LTD. (JP) | 1994-12-13 | — | — | US | disclosed |
| US-5089491-A | Active against both gram-negative and gram-positive bacteria | EISAI CO., LTD. (JP) | 1992-02-18 | — | — | US | disclosed |
| EP-0264091-B1 | 3-PROPENYLCEPHEM DERIVATIVE, PREPARATION THEREOF, CHEMICAL INTERMEDIATES THEREIN, PHARMACEUTICAL COMPOSITION AND USE | Eisai Co., Ltd. (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-5066812-A | Chemical intermediates for bactericides | EISAI CO., LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| US-5006649-A | Bactericides | EISAI, CO. (JP) | 1991-04-09 | — | — | US | disclosed |
| US-4921850-A | GRAMNEGATIVE AND GRAMPOSITIVE BACTERICIDE | EISAI CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0329785-A1 | CEPHALOSPORIN DERIVATIVES | Eisai Co., Ltd. (JP) | 1989-08-30 | — | — | EP | disclosed |
| EP-0264091-A2 | 3-Propenylcephem derivative, preparation thereof, chemical intermediates therein, pharmaceutical composition and use | Eisai Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | CA1 806/4885CA2 453/4885POLB 1902/4885 |
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | NLRP3, NOD1, PYCARD | CA1 2921/4885CA2 1151/4885POLB 4795/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | CA1 4810/4885CA2 4355/4885POLB 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.